查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1963885

支氣管炎治療市場－全球產業規模、佔有率、趨勢、機會、預測：按藥物類型、類別、最終用戶、地區和競爭格局分類，2021-2031年

Bronchitis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Class of Drugs, By Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球支氣管炎治療市場預計將從 2025 年的 85.7 億美元成長到 2031 年的 116.9 億美元，複合年成長率為 5.31%。

該領域涵蓋多種旨在減輕支氣管發炎和改善呼吸功能的藥物，例如支氣管擴張劑、抗發炎藥物、抗生素和祛痰藥。市場成長的主要驅動力是呼吸系統疾病盛行率的上升，而這又歸因於全球人口老化、持續的菸草消費以及日益嚴重的環境污染。根據國際藥學聯合會2024年的數據，全球約有3.91億人將患有慢性阻塞性肺病（COPD），這是一種以慢性支氣管炎為主要特徵的疾病，凸顯了對有效治療和管理藥物的迫切需求。

市場概覽
預測期 2027-2031
市場規模：2025年 85.7億美元
市場規模：2031年 116.9億美元
複合年成長率：2026-2031年 5.31%
成長最快的細分市場 醫院藥房
最大的市場 北美洲

儘管市場需求強勁，但主要品牌藥專利到期給市場帶來了巨大挑戰。隨之而來的是，大量價格低廉的學名藥湧入市場，導致激烈的價格競爭，從而減少主要生產商的收入。這種財務壓力可能會削弱企業對新藥研發進行大規模投資的意願，而這些新藥研發對於市場的持續擴張至關重要。

市場促進因素

環境污染物和菸草煙霧暴露量的增加是全球支氣管炎治療市場的主要驅動力，直接導致慢性呼吸系統疾病發生率上升。持續吸入菸草煙霧和空氣中的粒狀物會導致持續性支氣管發炎和黏液分泌過多，需要長期藥物治療。這種因果關係確保了支氣管炎治療擁有穩定的患者群體，尤其是在污染嚴重的低度開發地區。根據世界衛生組織（世衛組織）2024年1月發布的《2000-2030年全球菸草使用趨勢報告》，全球約有12.5億成年人被認定為菸草使用者，構成了一個龐大的高危險群，他們極易患上慢性支氣管炎，需要長期藥物治療。

同時，新型藥物製劑和吸入技術的進步正在推動市場創新，與傳統支氣管擴張劑相比，這些藥物療效更佳。研發人員正日益專注於標靶生物製藥和磷酸二酯酶抑制劑，這些藥物作用於特定的發炎通路，進而提高患者依從性和臨床療效。 2024年6月，Verona Pharma發布新聞稿，宣布了一項重要的里程碑：該公司宣布，Otuvia（恩西芬特林）——20多年來首個具有全新作用機制的用於慢性阻塞性肺部疾病（COPD）維持治療的吸入藥物——已獲得美國食品藥品監督管理局（FDA）的核准。此外，這些先進治療方法的商業性成功也顯而易見。 2024年，賽諾菲報告稱，其生物製藥Dupixent上半年全球銷售額達61億歐元，凸顯了新一代呼吸系統療法的巨大盈利潛力。

市場挑戰

全球支氣管炎治療市場正面臨重大挑戰，主要品牌藥的專利到期是一大障礙。這使得價格低廉的學名藥能夠迅速進入市場。這種轉變迫使原廠藥生產商在激烈的價格競爭環境中展開角逐，儘管處方量依然很高，但現有藥物的市場價值卻在下降。由此導致的收入減少顯著降低了製藥公司的投資回報率，並直接阻礙了研發支氣管疾病新治療方法所需的巨額資本投入。

這項挑戰的嚴峻性顯而易見，因為低成本競爭對手佔據的市場佔有率與其收入貢獻不成比例。根據美國可及藥品協會 (Association for Accessible Medicines) 2024 年的報告，學名藥和生物類似藥占美國所有處方箋的 90%，但僅佔藥品總支出的 12%。這種驚人的統計差異凸顯了品牌藥生產商難以獲得盈利，進而阻礙了他們為推動市場發展而進行的新療法創新投資。

市場趨勢

在全球支氣管炎治療市場，將吸入型皮質類固醇、長效毒蕈鹼受體拮抗劑和長效BETA2受體激動劑整合於單劑量吸入系統中的固定劑量三重吸入劑的使用正在迅速成長。這一趨勢正在重塑維持治療的基礎，簡化了複雜的用藥方案，並解決了重症慢性支氣管炎患者使用多種吸入劑聯合聯合治療時依從性低的問題。這些簡化的療法在預防病情加重方面展現出卓越的臨床效用，商業性應用正在加速超越傳統的雙聯療法。例如，葛蘭素史克（GSK）於2025年2月發布的《2024年全年及第四季度報告》顯示，其單吸入三聯療法Trelezy Ellipta的全球銷售額同比成長27%，這表明簡化治療通訊協定的市場正在快速擴張。

同時，對於儘管接受了最大劑量藥物治療但症狀仍然持續的患者，採用微創呼吸介入設備正成為重要的治療趨勢。這些基於設備的治療方法，包括支氣管成形術和液態氮冷凍療法，提供了一種非藥物機制，可以清除肥大的杯狀細胞並減少慢性支氣管炎特有的粘液過度分泌。這項進展標誌著治療策略從單純抑制症狀轉向針對氣道阻塞潛在病理病理學的介入治療。 2024年7月，CSA Medical在新聞稿中宣布，其RejuvenAir系統（專門用於治療慢性支氣管炎的冷凍手術設備）的SPRAY-CB III期臨床試驗已完成患者招募，該試驗在美國和歐洲共招募了210名受試者。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球支氣管炎治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 藥物分類（抗生素、抗發炎藥、支氣管擴張劑、其他）
    • 依類型（急性支氣管炎、慢性支氣管炎）
    • 依最終用戶（醫院藥局、零售藥局、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美支氣管炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲支氣管炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區支氣管炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲支氣管炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲支氣管炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球支氣管炎治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AstraZeneca PLC
  • Novartis AG
  • GSK PLC
  • Dr. Reddy's Laboratories Ltd
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc
  • Melinta Therapeutics Inc
  • Lupin Ltd
  • Cadila Pharmaceuticals Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18856

The Global Bronchitis Treatment Market is projected to expand from USD 8.57 Billion in 2025 to USD 11.69 Billion by 2031, reflecting a compound annual growth rate of 5.31%. This sector encompasses a range of pharmaceutical interventions, such as bronchodilators, anti-inflammatory agents, antibiotics, and mucolytics, all aimed at reducing bronchial inflammation and enhancing respiratory function. The market's growth is largely fueled by the rising prevalence of respiratory disorders attributed to aging populations worldwide, continued tobacco consumption, and increasing environmental pollution. Data from the International Pharmaceutical Federation in 2024 indicates that roughly 391 million individuals globally were living with chronic obstructive pulmonary disease, a major condition involving chronic bronchitis, highlighting the urgent and escalating demand for effective therapeutic management.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 8.57 Billion
Market Size 2031USD 11.69 Billion
CAGR 2026-20315.31%
Fastest Growing SegmentHospital Pharmacies
Largest MarketNorth America

Despite this robust demand, the market encounters significant obstacles related to the expiration of patents for key branded therapeutics. The subsequent influx of cost-effective generic alternatives leads to intense pricing competition and a decline in revenue streams for major manufacturers. This financial strain can disincentivize substantial investment in the research and development of novel drug classes that are essential for continued market expansion.

Market Driver

Rising exposure to environmental pollutants and cigarette smoke serves as a primary driver for the Global Bronchitis Treatment Market, directly increasing the incidence of chronic respiratory conditions. Continuous inhalation of tobacco smoke and airborne particulates causes persistent bronchial inflammation and excessive mucus production, necessitating long-term pharmacological management. This causal link ensures a steady patient base for bronchitis therapeutics, particularly in developing regions with high pollution levels. According to the World Health Organization's 'Global Report on Trends in Prevalence of Tobacco Use 2000-2030' released in January 2024, approximately 1.25 billion adults globally were identified as tobacco users, creating a massive demographic susceptible to developing chronic bronchitis and requiring maintenance therapy.

Concurrently, the market is being revolutionized by advancements in novel drug formulations and inhalation technologies, which offer superior efficacy compared to traditional bronchodilators. Developers are increasingly focusing on targeted biologics and phosphodiesterase inhibitors that address specific inflammatory pathways, thereby improving patient compliance and clinical outcomes. A significant milestone was noted by Verona Pharma in a June 2024 press release, announcing FDA approval for Ohtuvayre (ensifentrine), the first inhaled product with a novel mechanism of action for COPD maintenance available in over 20 years. Furthermore, the commercial success of these advanced therapies is evident; Sanofi reported in 2024 that the biologic drug Dupixent generated global sales of €6.1 billion in the first half of the year, underscoring the lucrative potential of next-generation respiratory treatments.

Market Challenge

The Global Bronchitis Treatment Market faces a critical hurdle due to the patent expiration of key branded therapeutics, which triggers the immediate entry of cost-effective generic alternatives. This shift compels original manufacturers to compete in an environment characterized by intense pricing pressure, causing the market value of established drugs to fall even as prescription volumes remain high. The resulting erosion of revenue streams significantly reduces the return on investment for pharmaceutical companies, directly discouraging the substantial financial commitment required to discover and develop novel treatments for bronchial conditions.

The magnitude of this challenge is illustrated by the disproportionate market share held by lower-cost competitors compared to their revenue contribution. According to the Association for Accessible Medicines in 2024, generic and biosimilar medicines accounted for 90 percent of all prescriptions filled in the United States while comprising only 12 percent of total drug spending. This sharp statistical disparity demonstrates the difficulty branded manufacturers encounter in securing profitable returns, thereby hampering the investment necessary to drive the market forward with new therapeutic innovations.

Market Trends

The Global Bronchitis Treatment Market is experiencing a robust shift toward the increasing utilization of fixed-dose triple combination inhalers, which consolidate an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-agonist into a single administration system. This trend is fundamentally reshaping maintenance therapy by simplifying complex medication schedules, thereby resolving poor adherence issues associated with multi-inhaler regimens in patients with severe chronic bronchitis. The superior clinical utility of these streamlined therapies in preventing exacerbations has accelerated their commercial uptake over conventional dual therapies. For instance, GSK's 'Full-year and fourth quarter 2024' report from February 2025 noted that global sales of the single-inhaler triple therapy Trelegy Ellipta grew by 27 percent compared to the previous year, demonstrating the rapid market expansion of simplified treatment protocols.

Simultaneously, the adoption of minimally invasive interventional pulmonology devices is emerging as a critical trend for managing patients who remain symptomatic despite maximal pharmacological intervention. These device-based therapies, including bronchial rheoplasty and liquid nitrogen cryospray, offer a non-drug mechanism to ablate hyperplastic goblet cells and reduce the mucus hypersecretion that characterizes chronic bronchitis. This development marks a pivot toward procedural solutions that target the underlying pathophysiology of airway obstruction rather than merely suppressing symptoms. In July 2024, CSA Medical announced in a press release the successful completion of patient enrollment for the SPRAY-CB pivotal trial of the RejuvenAir System, a cryosurgical device specifically developed to treat chronic bronchitis, involving 210 subjects across the United States and Europe.

Key Market Players

  • AstraZeneca PLC
  • Novartis AG
  • GSK PLC
  • Dr. Reddy's Laboratories Ltd
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc
  • Melinta Therapeutics Inc
  • Lupin Ltd
  • Cadila Pharmaceuticals Ltd

Report Scope

In this report, the Global Bronchitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bronchitis Treatment Market, By Class of Drugs

  • Antibiotics
  • Anti-inflammatory Drugs
  • Bronchodilator
  • Others

Bronchitis Treatment Market, By Type

  • Acute Bronchitis
  • Chronic Bronchitis

Bronchitis Treatment Market, By End User

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Bronchitis Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bronchitis Treatment Market.

Available Customizations:

Global Bronchitis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bronchitis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Class of Drugs (Antibiotics, Anti-inflammatory Drugs, Bronchodilator, Others)
    • 5.2.2. By Type (Acute Bronchitis, Chronic Bronchitis)
    • 5.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Bronchitis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Class of Drugs
    • 6.2.2. By Type
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bronchitis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Class of Drugs
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Bronchitis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Class of Drugs
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Bronchitis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Class of Drugs
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By End User

7. Europe Bronchitis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Class of Drugs
    • 7.2.2. By Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bronchitis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Class of Drugs
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End User
    • 7.3.2. France Bronchitis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Class of Drugs
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Bronchitis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Class of Drugs
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Bronchitis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Class of Drugs
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Bronchitis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Class of Drugs
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By End User

8. Asia Pacific Bronchitis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Class of Drugs
    • 8.2.2. By Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Bronchitis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Class of Drugs
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End User
    • 8.3.2. India Bronchitis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Class of Drugs
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Bronchitis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Class of Drugs
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Bronchitis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Class of Drugs
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Bronchitis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Class of Drugs
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End User

9. Middle East & Africa Bronchitis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Class of Drugs
    • 9.2.2. By Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Bronchitis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Class of Drugs
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Bronchitis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Class of Drugs
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Bronchitis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Class of Drugs
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End User

10. South America Bronchitis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Class of Drugs
    • 10.2.2. By Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Bronchitis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Class of Drugs
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Bronchitis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Class of Drugs
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Bronchitis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Class of Drugs
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Bronchitis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AstraZeneca PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. GSK PLC
  • 15.4. Dr. Reddy's Laboratories Ltd
  • 15.5. Sanofi SA
  • 15.6. Boehringer Ingelheim International GmbH
  • 15.7. Pfizer Inc
  • 15.8. Melinta Therapeutics Inc
  • 15.9. Lupin Ltd
  • 15.10. Cadila Pharmaceuticals Ltd

16. Strategic Recommendations

17. About Us & Disclaimer